medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2018, Number S1

<< Back Next >>

Acta Pediatr Mex 2018; 39 (S1)

Epidemiology of phenylketonuria obtained through neonatal screening

Vela-Amieva M, Ibarra-González I, Herrera-Pérez LA, Caamal-Parra G, Belmont-Martínez L, García-Flores EP

Language: Spanish
References: 29
Page: 25-34
PDF size: 557.33 Kb.


ABSTRACT

Introduction: Hyperphenylalaninemia, whose most serious form is phenylketonuria (PKU) is an inborn error of phenylalanine (Phe) metabolism. If untreated, results in profound and irreversible mental disability. In Mexico, early detection of this disease was incorporated into the newborn screening program (NBS) of the Ministry of Health in 2011.
Objective: To present for first time the birth prevalence of hyperphenylalaninemia (HPA) and phenylketonuria (PKU) obtained through newborn screening in Mexico.
Material and Methods: From January 1st, 2017 to May 31, 2018, a total of 1,273,727 samples were taken from the heel of newborns (NB) attended by the Ministry of Health of Mexico. Phe was quantified in dry blood by immunofluorometric assay. All the NB with positive screening and whose confirmatory tests showed elevated levels of PHE in blood, low tyrosine (Tyr) and PHE/Tyr ratio ›2, where considered as confirmed cases of the disease. The number of HPA/PKU positive screening cases, confirmed cases, false positives as well as the proportion of non-localized cases were analyzed. The statistical analysis was carried out through the free access program Comprehensive R Archive Network.
Results: A total of 1,267,122 (99.4%) samples were adequate for Phe quantification from them, 793 were above the cut-off value and were notified as positive screening test. 46 HPA/PKU cases were confirmed. The disease was present in 21 Mexican states.
Conclusions: HPA/PKU birth prevalence rate in México was 3.6 cases per 100.000 newborns, which is equivalent to 1 case in each 27,546 screened NB.


REFERENCES

  1. Blau N, Van Spronsen F, Levy H. Phenylketonuria. The Lancet, 2010; 376(9750):1417-1427.

  2. Scriver C.R. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. En The Metabolic and Molecular Bases of Inherited Disease. 8a Edición, Scriver C, Beaudet AL, Sly W, Valle D, eds. MacGrawHill, NY, USA, 2001; Vol. 2, pp. 1667-1724.

  3. Belmont-Martínez L, Fernández-Lainez C, Ibarra-González I, Guillén-López S, Monroy-Santoyo S, Vela-Amieva M. Evaluación bioquímica de la fenilcetonuria (PKU): del diagnóstico al tratamiento. Acta Pediatr Mex 2012; 33(6):296-300.

  4. de Groot MJ, Hoeksma M, Blau N, Reijngoud DJ, van Spronsen FJ. Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses. Mol Genet Metab. 2010; 99 Suppl 1:S86-9.

  5. van Spronsen FJ. Phenylketonuria: a 21st century perspective. Nat Rev Endocrinol. 2010; 6(9):509-14.

  6. Khemir S, Soumeyya H, Azzouz H, Siala H, Ferchichi M, Guedria A, et al. Autism in Phenylketonuria Patients: from clinical presentation to molecular defects. J. Child Neurology 2016 31(7):843-849.

  7. Følling A. 1934. Uber Ausscheidung von Phenylbrenztraubensaure in denHarn als Stoffwechselanomalie in Verbindung mit Imbezillitat. HoppeSeylers Z Physiol Chem 277:169-176.

  8. Følling I. The discovery of phenylketonuria. Acta Pediatr Suppl. 1994; 407:4-10.

  9. Bickel H, Gerrard J, Hickmans EM. The influence of phenylalanine intake on phenylketonuria. Lancet 1953;265(6790):812-3

  10. Woolf LI, Griffiths R, Moncrieff A. Treatment of phenylketonuria with a diet low in phenylalanine. Br Med J. 1955; 1(4905):57-64.

  11. Guthrie R, Susi A. A Simple Phenylalanine Method for Detecting Phenylketonuria in Large Populations of Newborn Infants. Pediatrics. 1963; 32:338-43.

  12. Tamiz Neonatal. Detección, Diagnóstico, Tratamiento y Seguimiento de los Errores Innatos del Metabolismo. Lineamiento Técnico, Centro Nacional de Equidad de Género y Salud Reproductiva, Secretaría de Salud, México 2010. 96 pp.

  13. Singh RH, Cunningham AC, Mofidi S, Douglas TD, Frazier DM, Hook DG, et al. Updated, web-based nutrition management guideline for PKU: An evidence and consensus based approach Mol Genet Metab. 2016; 118(2):72-83.

  14. van Wegberg AMJ, MacDonald A, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017; 12(1):162.

  15. Grosse S.D., Rogowski W.H., Ross L.F., Cornel M.C., Dondorp W.J., Khoury M.J. Population screening for genetic disorders in the 21st century: Evidence, economics, and ethics. Public Health Genomics. 2010; 13(2):106-115.

  16. Grosse SD. Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis. Healthcare (Basel). 2015; 3(4):1133-57.

  17. Brosco JP, Grosse SD, Ross LF. Universal state newborn screening programs can reduce health disparities. JAMA Pediatr. 2015; 169(1):7-8.

  18. CDC. Ten great public health achievements. United States 2001-2010. Morbidity and Mortality Weekly Report. 2011; 60:619-23.

  19. Borrajo GJ. Newborn screening in Latin America at the beginning of the 21st century. J Inherit Metab Dis. 2007; 30(4):466-81.

  20. Borrajo GJC. Panorama epidemiológico de la fenilcetonuria (PKU) en Latinoamérica. Acta Pediatr Mex 2012; 33(6):279-287.

  21. Secretaría de Salud, Diario Oficial de la Federación. Ley General de Salud, Artículo 61, Fracción II, reforma del 25/01/2013.

  22. Norma Oficial Mexicana NOM-034-SSA2-2013, Para la prevención y control de los defectos al nacimiento. Diario Oficial de la Federación, 24/06/2014, México.

  23. Norma Oficial Mexicana NOM-007-SSA2-2016, Para la atención de la mujer durante el embarazo, parto y puerperio, y de la persona recién nacida. Diario Oficial de la Federación, 01/04/2016, México.

  24. Velázquez A, Bilbao G, González-Trujillo JL, Hernández D, Pérez-Andrade ME, Vela M, et al. Apparent higher frequency of phenylketonuria in the Mexican state of Jalisco. Hum Genet.1996; 97(1):99-102.

  25. Vela-Amieva M, Abreu-González M, González-del Angel A, Ibarra-González I, Fernández-Lainez C, Barrientos-Ríos R, et al. Phenylalanine hydroxylase deficiency in Mexico: genotype-phenotype correlations, BH4 responsiveness and evidence of a founder effect. Clin Genet. 2015; 88(1):62-7.

  26. González Guerrero J, Delgado González E, Burciaga Torres M, Mendiola Ramírez K, Ferrer Arreola L. Phenylketonuria Newborn Screening Experience in Mexico Epidemiological Overview. JIEMS Special Supplement, 2015: 53.

  27. Zaffanello M, Zamboni G, Maffeis C, Tatò L. Neonatal birth parameters of positive newborns at PKU screening as predictors of false-positive and positive results at recall- testing. J Med Screen. 2003; 10(4):181-3.

  28. Hewlett J, Waisbren SE. A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening. J Inherit Metab Dis. 2006; 29(5):677-82.

  29. Known C, Farrell PM. The magnitude and challenge of false-positive newborn screening results. Arch Pediatr Adolesc Med. 2000;154(7):714–18




2020     |     www.medigraphic.com